ACHN Awaits PNH Data, Avita Gears Up For PMA Filing, SSKN Effects Reverse Split

Achillion Pharma expects to report interim results from its phase II study of ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria during this quarter.

from RTT - Biotech http://ift.tt/2oPJzrQ
via IFTTT